Tianjin Zhong Xin Pharmaceutical expects up to 60% profit increase

The profit guidance is based on a preliminary review of unaudited financial results.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited announced that it expects to report a strong profit for the third quarter of the financial year ending 31 December 2012.

The net profit of the Group for the third quarter of FY2012 is expected to increase by approximately 40% to 60% over the previous corresponding period due to the gain on disposal of the company’s subsidiary, being Tianjin Central Pharmaceutical Co., Ltd.; increase in the return on investment from the company’s associated companies, Sino-American Tianjin Smithkline & French Lab., Ltd.; and increase in operating profits from the Group’s main business.